|
||
| |||||||
|
Proteom and 14TM announce a strategic partnership in GPCR ligand design Cambridge,UK, 28th October, 2004 Proteom Ltd, an in silico molecular design company, and 14TM Ltd, a GPCR structure and function company, today announced a strategic partnership, initially focused on the design of novel ligands to a range of GPCR targets.14TM has proprietary models of active and inactive GPCRs and extensive knowledge of ligand binding sites in many receptor subtypes. Model structures provided by 14TM will be used with Proteom’s proprietary in silico ProtoScreen™ screening and ProtoBuild™ de novo design applications for the design of new ligands. "We are very pleased to be able to enter into this strategic partnership with 14TM,” said Dr Bill Hamilton, COO of Proteom, “it will allow us to exploit the synergy between the technology bases of our two companies and enable us to design novel ligands to GPCR targets of major pharmaceutical interest. We have been interested in getting into this area for some time as it will extend the range of targets that we have been working on as part of a number of commercial projects that we have completed in the last year”. Dr Robert Bywater, CEO 14TM added: “The two companies have perfectly matching technologies and complementary skill sets. All the initial work has demonstrated that the combined technologies are capable of finding new ligands for GPCRs.” --- Ends --- Note to EditorAbout Proteom LimitedProteom Ltd is Cambridge (UK)-based biotechnology company specializing in the in silico design of small molecule ligands. The Company’s state-of-the-art technology platform includes ProtoBuild™, a de novo design application, and ProtoScreen™, a virtual screening tool. Proteom currently provides in silico design/screening services to companies requiring cutting edge computational design capabilities for their drug discovery programs. For more information about Proteom, please contact: William D.O. Hamilton Proteom Limited About 14TM Limited14TM Ltd is a company specialising in the structure and function of GPCRs (G-Protein Coupled Receptors) and other proteins important in Drug Discovery. The Company has a number of technologies that can be used in structure based drug design, including active and inactive receptor models, phylogenetic tools for the prediction of subtype specificity and receptor de-orphanisation. For further information about 14TM, please contact: Robert Bywater PhD 14TM Ltd
|
|
| ||||||||